Protagonist Therapeutics, Inc. is a biotechnology company focused on developing novel peptide-based therapeutics for gastrointestinal and other diseases. Its lead product candidate, PTG-300, is in clinical trials for the treatment of anemia associated with chronic kidney disease, which positions the company uniquely in a niche market with high unmet medical needs.
Protagonist Therapeutics primarily generates revenue through partnerships and collaborations with larger pharmaceutical companies for the development of its drug candidates. The high gross margin of 97.3% indicates significant pricing power once products reach commercialization, supported by a strong intellectual property portfolio.
Clinical trial results for PTG-300 and other candidates
Partnership announcements with larger pharmaceutical firms
Regulatory approvals from the FDA
Market adoption rates of approved therapies
Regulatory changes affecting drug approval processes
Technological disruption in drug development methodologies
Emerging competitors developing similar peptide-based therapies
Potential for larger pharmaceutical companies to dominate the market
High cash burn rate leading to potential liquidity issues
Dependence on external funding for ongoing clinical trials
low - The biotechnology sector is generally less sensitive to economic cycles as healthcare spending tends to remain stable regardless of economic conditions.
Moderate - Rising interest rates could increase the cost of capital for funding R&D, impacting the company's ability to finance clinical trials.
minimal - The company has a low debt-to-equity ratio of 0.01, indicating minimal reliance on external credit.
growth - Investors looking for high-risk, high-reward opportunities in biotechnology.
high - The stock has experienced significant price fluctuations, evidenced by a 94.7% return over the past year.